Prime Medicine (PRME) News Today $5.61 -0.04 (-0.71%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 23 at 1:24 PM | marketbeat.comPrime Medicine (NYSE:PRME) Trading 5.4% Higher Prime Medicine (NYSE:PRME) Trading Up 5.4%July 18, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Trading Down 6.4%Prime Medicine (NYSE:PRME) Stock Price Down 6.4%July 18, 2024 | americanbankingnews.comPrime Medicine (NYSE:PRME) Shares Gap Up to $5.78July 12, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 4.8%Prime Medicine (NYSE:PRME) Trading Down 4.8%July 11, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 6.5%Prime Medicine (NYSE:PRME) Stock Price Up 6.5%July 10, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Upgraded to Sell by StockNews.comStockNews.com raised Prime Medicine to a "sell" rating in a research report on Wednesday.July 9, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Sells 154,366 Shares of Prime Medicine, Inc. (NYSE:PRME)Sumitomo Mitsui Trust Holdings Inc. lessened its stake in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 4.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,364,663 shares of the company's stock after selling 154,366 sharJuly 8, 2024 | insidermonkey.comPrime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?June 26, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Down 7% Prime Medicine (NYSE:PRME) Stock Price Down 7%June 25, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Lifted to "Sell" at StockNews.comStockNews.com raised shares of Prime Medicine to a "sell" rating in a report on Tuesday.June 24, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Trading 5.2% Higher Prime Medicine (NYSE:PRME) Shares Up 5.2%June 20, 2024 | seekingalpha.comPrime Medicine Stock: Only For The Most Patient Of InvestorsJune 19, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by AnalystsPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation toJune 17, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Down 5.8% Prime Medicine (NYSE:PRME) Shares Down 5.8%June 10, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 6.8%Prime Medicine (NYSE:PRME) Stock Price Up 6.8%June 6, 2024 | marketbeat.com361,136 Shares in Prime Medicine, Inc. (NYSE:PRME) Purchased by Bollard Group LLCBollard Group LLC acquired a new position in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 361,136 shares of the company's stock, valued at aJune 3, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Forecasted to Earn FY2024 Earnings of ($1.68) Per SharePrime Medicine, Inc. (NYSE:PRME - Free Report) - Analysts at Chardan Capital issued their FY2024 earnings per share (EPS) estimates for shares of Prime Medicine in a report released on Wednesday, May 29th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings per shaMay 29, 2024 | investorplace.comIf You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 NamesMay 28, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up to $6.93Prime Medicine (NYSE:PRME) Shares Gap Up to $6.93May 25, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Moderate Buy" by BrokeragesShares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and ten have issuedMay 25, 2024 | fool.comHere Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion PortfolioMay 24, 2024 | finance.yahoo.comPrime Medicine, Inc. (PRME)May 22, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Trading Down 3.9%Prime Medicine (NYSE:PRME) Shares Down 3.9%May 22, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) to Post Q2 2024 Earnings of ($0.40) Per Share, HC Wainwright ForecastsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at HC Wainwright issued their Q2 2024 earnings estimates for shares of Prime Medicine in a research report issued on Monday, May 20th. HC Wainwright analyst A. He anticipates that the company will earn ($0.40) per share for the quMay 21, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Prime Medicine (PRME) with Buy RecommendationMay 20, 2024 | marketbeat.comHC Wainwright Begins Coverage on Prime Medicine (NYSE:PRME)HC Wainwright assumed coverage on shares of Prime Medicine in a research note on Monday. They issued a "buy" rating and a $10.00 target price for the company.May 17, 2024 | marketbeat.comNikko Asset Management Americas Inc. Sells 115,819 Shares of Prime Medicine, Inc. (NYSE:PRME)Nikko Asset Management Americas Inc. cut its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,519,029 shares of the coMay 17, 2024 | msn.comCitigroup Upgrades Prime Medicine (PRME)May 17, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 17, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 16, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 4.1%Prime Medicine (NYSE:PRME) Shares Up 4.1%May 16, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Upgraded at CitigroupCitigroup upgraded shares of Prime Medicine from a "neutral" rating to a "buy" rating and set a $10.00 target price on the stock in a report on Thursday.May 15, 2024 | msn.comWhat is Prime Day, exactly? How Amazon's giant deals day worksMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on FDA Trial Approval and Strong FinancialsMay 13, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up to $5.61Prime Medicine (NYSE:PRME) Shares Gap Up to $5.61May 13, 2024 | marketbeat.comJPMorgan Chase & Co. Trims Prime Medicine (NYSE:PRME) Target Price to $15.00JPMorgan Chase & Co. decreased their price target on Prime Medicine from $16.00 to $15.00 and set an "overweight" rating for the company in a report on Monday.May 13, 2024 | globenewswire.comPrime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finanznachrichten.dePrime Medicine, Inc.: Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Robust Preclinical Data and Prime Editing Technology ProspectsMay 10, 2024 | investorplace.comPRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024May 10, 2024 | msn.comPrime Medicine GAAP EPS of -$0.44 beats by $0.03, revenue of $0.59M misses by $0.32MMay 10, 2024 | globenewswire.comPrime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 8, 2024 | globenewswire.comPrime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)May 7, 2024 | marketbeat.comPrime Medicine's (PRME) "Buy" Rating Reiterated at Jefferies Financial GroupJefferies Financial Group restated a "buy" rating and set a $15.00 price objective (down previously from $23.00) on shares of Prime Medicine in a report on Tuesday.May 6, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 2.5%Prime Medicine (NYSE:PRME) Stock Price Down 2.5%May 6, 2024 | marketbeat.com144,288 Shares in Prime Medicine, Inc. (NYSE:PRME) Bought by Vestmark Advisory Solutions Inc.Vestmark Advisory Solutions Inc. acquired a new stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 144,288 shares of the company's stock, valued at approximately $1,278,May 1, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 5.7%Prime Medicine (NYSE:PRME) Trading 5.7% HigherApril 29, 2024 | msn.comFDA clears Prime Medicine to begin gene therapy clinical testingApril 29, 2024 | marketwatch.comPrime Medicine Shares Rise 13% After FDA Clears IND ApplicationApril 29, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up to $4.43Prime Medicine (NYSE:PRME) Shares Gap Up to $4.43 Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address How to build the ultimate dividend portfolio (Ad)There’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again. Click here and I’ll show you how to build the ultimate dividend portfolio. PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.510.62▲Average Medical News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼12▲PRME Articles Average Week Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vericel News CG Oncology News Iovance Biotherapeutics News Beam Therapeutics News Immunocore News Novavax News Recursion Pharmaceuticals News Neumora Therapeutics News BioCryst Pharmaceuticals News Vir Biotechnology News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
